| __timestamp | Travere Therapeutics, Inc. | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 47795223 | 18516000 |
| Thursday, January 1, 2015 | 50426000 | 34140000 |
| Friday, January 1, 2016 | 70853000 | 51872000 |
| Sunday, January 1, 2017 | 78168000 | 71772000 |
| Monday, January 1, 2018 | 123757000 | 97501000 |
| Tuesday, January 1, 2019 | 140963000 | 118590000 |
| Wednesday, January 1, 2020 | 131773000 | 169802000 |
| Friday, January 1, 2021 | 210328000 | 192507000 |
| Saturday, January 1, 2022 | 235780000 | 199563000 |
| Sunday, January 1, 2023 | 244990000 | 253598000 |
Infusing magic into the data realm
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Travere Therapeutics, Inc. and Xencor, Inc. have demonstrated significant growth in their R&D budgets, reflecting their dedication to advancing medical breakthroughs.
From 2014 to 2023, Travere Therapeutics increased its R&D expenses by over 400%, starting from a modest $47.8 million to a substantial $244.9 million. Similarly, Xencor, Inc. saw a remarkable rise of over 1,200%, with its R&D spending climbing from $18.5 million to $253.6 million. This upward trend underscores the escalating investment in developing novel therapies and treatments.
As these companies continue to push the boundaries of science, their growing R&D budgets highlight the dynamic nature of the biotech industry and its relentless pursuit of innovation.
Comparing Innovation Spending: Novo Nordisk A/S and Travere Therapeutics, Inc.
Merck & Co., Inc. vs Travere Therapeutics, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Pfizer Inc. and Travere Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Xencor, Inc.
Analyzing R&D Budgets: Pharming Group N.V. vs Travere Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Alpine Immune Sciences, Inc. and Xencor, Inc.
R&D Spending Showdown: Ultragenyx Pharmaceutical Inc. vs Xencor, Inc.
R&D Insights: How Rhythm Pharmaceuticals, Inc. and Xencor, Inc. Allocate Funds
Comparing Innovation Spending: Veracyte, Inc. and Travere Therapeutics, Inc.
Comparing Innovation Spending: Vericel Corporation and Xencor, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Soleno Therapeutics, Inc. and Xencor, Inc.
R&D Spending Showdown: Evotec SE vs Xencor, Inc.